Attacking NHL Early

" About 40%. Of non hodgkin's lymphoma are non aggressive or -- forms of the disease. Well into Clinton and Obama at around it isn't let's immediate danger to a patient and more regret it forms you generally is not curable."

" beginning to -- lymphoma. Ideally we would like to get rid of it. It is in a little lymphoma a very difficult thing to do people with the disease. Many many years and I think a realistic goal is to try to make it a chronic -- and that this. And long term traction where he can handle at a relatively normal -- and."

" Sometimes doctors and patients to her treatment opting instead to monitor the -- carefully. When treatment does become very the traditional course has been chemotherapy. Beginning in the late 1990s. Doctors began adding another type of drug what's called an anti CD twenty monoclonal antibodies. England installments the drug called -- and that has been approved for recurrent or resistant disease. But research shows it can also be used earlier on."

" You know on some other combination. In the average at -- When he monoclonal antibody. We cannot bear it has. Several studies demonstrated it. Higher rate of overall response. Improves equality response. And ends at that time. To aggression."

" Listening to time to progression however does not automatically mean a patient will live longer. Doctors say to your hand from clinical trial data that retire and that -- in case is increased survival but it really tune in detail."

" I think in the inquest in EU's. The long term and for many people the ultimate goal is to be -- And do well in the long term decades now and it's still too early in the games so to speak as a -- what -- you. In the long term and forty years were encouraged. About the short term benefits and hope that ate translate into long term. But we need to -- rather. Than it."

" Monoclonal antibody has you -- districts except flu like symptoms while it is being administered. As a result some doctors try using it alone as mono therapy especially in cases where watchful waiting might be the alternative."

" The prospects. Not having treatment that's effective. And -- relatively nontoxic and has skeletons in the therapy. In a way that patients. And their positions. We'll look at the policy. A lot of -- And under the second and says -- an appropriate. -- is an -- and that's single and there. And again this isn't it is -- kind clinical trials. About the United Europe."

" I know the role monoclonal antibodies may be too prolonged remission what's sometimes called maintenance therapy. Sometimes that means extending the use of -- and that's when he used as initial therapy. Another maintenance approach is to -- monoclonal antibodies following chemotherapy."

" 11 possibility with treatment and ordered her long time -- is perhaps you can. Give initial treatment. Get somebody remission. And then continue to get treatment and -- intermittently. Horror. Even at a low level perhaps for her long time in an and that."

" Doctors at ten it's different treatment given excellent there. Known as maintenance or consolidation treatment -- and that -- more recently. I have a and that has employed as a means you try it. -- isn't that initially achieved by human -- In large clinical trial conducted at night at airports -- that was evident. To and had a combination that there is an randomized trial whether -- that appeared -- and the rich and that treatment actually further improved. The quality and -- And and it -- it each time -- to grant and."

" There's still some uncertainty about possible to win -- talks and that is used as long term maintenance therapy. That's because the original study only followed patients for two years. Whether or not they're are going to be keenly develop. Cumulative problem from using it. -- longer than clear. I think people -- back. But there isn't that doctors are investigating the use of several new drugs. Including different types of monoclonal antibody to improve treatment of non hodgkin's lymphoma. And even over -- that has already been demonstrated. Actors in many circumstances. It's a new enough drug that doctors are still learning about how to use it passed."

" I think that we made a lot of progress I think that these studies suggest that that we can improve upon either were -- somatic cell war we can improve on in therapy by Aaron it's a man adding we haven't yet -- what's the best way to use it but it clear that I mean different things and coming up with the new regiment. There we are. -- improving outcomes we are making progress but I think that delays too oh is that went bad when you use of this particular type of treatment."